Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells
Although malignant mesothelioma (MM) is rare among thoracic malignancies, approximately 1500 and 3000 patients are newly diagnosed each year in Japan and the United States [1], respectively. Treatment of MM, including surgery, radiotherapy, and chemotherapy, is recommended according to stage, performance status, pulmonary function, complications, and patient preference. First-line chemotherapy for advanced MM involves a combination of cisplatin and pemetrexed as the standard treatment. Although this combination has been proven to prolong survival over cisplatin alone in a phase III trial (12.1 months vs.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Noriko Miyake, Nobuaki Ochi, Hiromichi Yamane, Takuya Fukazawa, Tomoko Ikeda, Etsuko Yokota, Masami Takeyama, Nozomu Nakagawa, Hidekazu Nakanishi, Hiroyuki Kohara, Yasunari Nagasaki, Tatsuyuki Kawahara, Naruhiko Ichiyama, Tomoki Yamatsuji, Yoshio Naomoto, Source Type: research
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Japan Health | Lung Cancer | Mesothelioma | USA Health